supported by the National Science and Technology Major Project (No.2017ZX10202202 to JS and DKJ and 2018ZX10301202 to JH and DKJ);the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (No.2017BT01S131 to JH,JS and DKJ);the General Programs from the National Natural Science Foundation of China (No.81472618 to DKJ,81670535 to DKJ,and 81802833 to HC);the General Program from the Natural Science Foundation of Guangdong Province (No.2019A1515011423 to DKJ);the Key-Area Research and Development Program of Guangdong Province (No.2019B020227004 to DKJ);the Innovative Research Team Project of Guangxi Province (No.2017GXNSFGA198002 to DKJ);the Dean Fund of Nanfang Hospital,Southern Medical University (No.2018Z005 to DKJ);the Grant for Recruited Talents to Start Scientific Research from Nanfang Hospital,and the Outstanding Youth Development Scheme of Nanfang Hospital,Southern Medical University (No.2017J001 to DKJ).
Background and Aims:Only a small percentage of chronic hepatitis B(CHB)patients effectively respond to treatment with pegylated-interferon alpha(PegIFNα)or nucleos(t)ide analogues(NUCs).We aimed to detect the correla...
BACKGROUND Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues(NAs)rarely achieve hepatitis B surface antigen(HBsAg)loss.AIM To evaluate if the addition of pegylated interferon(Pe...
AIM To investigate peg-interferon(peg-IFN) and ribavirin(RBV) therapy in Myanmar and to predict sustained virologic response(SVR).METHODS This single-center, open-label, study was conducted in Myanmar between 2009 and...
Hepatitis C virus(HCV) genotype(GT) 4 represents 12%-15%(15-18 million) of total global HCV infection. It is prevalent in Northern and Equatorial Africa and the Middle East, and is also present in some countries in Eu...
Supported by The National Research University Project,Office of Higher Education Commission,Nos.WCU001-HR-57,WCU007-HR-57,and WCU-58-006-HR;The National Research Council of Thailand(NRCT);The Research Chair Grant from the National Science and Technology Development Agency,Chulalongkorn University Centenary Academic Development Project,No.CU56-HR01;Ratchadaphiseksomphot Endowment Fund of Chulalongkorn University,No.RES560530093;The Outstanding Professor of Thailand Research Fund,No.DPG5480002;The Doctoral Degree Chulalongkorn University 100~(th) Year Birthday Anniversary to Duangnapa Intharasongkroh;The Rachadapisek Sompote Fund of Chulalongkorn University for Postdoctoral Fellowship to Pattaratida Sa-nguanmoo
Hepatitis E virus(HEV) infection is now established as an emerging enteric viral hepatitis. Standard treatments in acute and chronic hepatitis E remain to be established. This study undertakes a review of the epidemio...
Supported by grants from Research Program of Intractable Disease provided by the Ministry of Health,Labor and Welfare of Japan,and a Grant-in-Aid for Clinical Research from the National Hospital Organization of Japan
AIM:To investigate the relationship between the ironmetabolism-related gene expression profiles and efficacy of antiviral therapy in chronic hepatitis C patients.METHODS:The hepatic expression profile of ironmetabolis...
Supported by Yassin Abdel-Ghaffar Charity Center for LiverDisease and Research,Cairo,Egypt,in collaboration with the National Liver Institute,Menofiya University,Egypt and Cairo University Pediatric Hospital,Cairo,Egypt;Antiviral medications(PEG-IFN-alpha-2a and ribavirin)and HCV genotyping were of-fered as donation from Yassin Abdel-Ghaffar Charity Center for Liver Disease and Research,Cairo,Egypt
AIM: To investigate the safety and efficacy of a Hansenula-derived PEGylated (polyethylene glycol) interferon (IFN)-alpha-2a (Reiferon Retard) plus ribavirin customized regimen in treatment-naïve and previousl...
Purpose: The optimal formulation of pegylated interferon a (PEG-IFa) as a part of combination therapy with ribavirin (RBV) is uncertain for patients infected with hepatitis C Genotypes 2 and 3. Methods: A multivariate...
AIM: To evaluate the efficacy and safety of pegylated- interferon alpha-2a in hemodialysis patients with chronic hepatitis C. METHODS: Thirty-six hemodialysis patients with chronic hepatitis C were enrolled in a con...
An estimated 300 million people worldwide suffer from chronic hepatitis C with a prevalence of 0.8%-1.0% of the general population in Canada. An increasing pool of evidence exists supporting the use of pegylated-inter...